Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Varlilumab - Celldex Therapeutics Inc

Next Previous
X
Search
Drug Profile

Varlilumab - Celldex Therapeutics Inc

Alternative Names: CDX-1127

Latest Information Update: 11 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celldex Therapeutics Inc
  • Developer Celldex Therapeutics Inc; National Cancer Institute (USA); Oncothyreon; University of California at San Francisco; University of Virginia
  • Class Antigens; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD27 antigen stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Biliary cancer; Glioblastoma; Malignant melanoma; Non-Hodgkin's lymphoma; Solid tumours
  • Phase I/II Renal cell carcinoma
  • No development reported Glioma; Haematological malignancies; Prostate cancer
  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 21 Aug 2024 University Hospital Southampton NHS Foundation Trust and Cancer Research UK in collaboration with Celldex completes the phase I/II RiVa trial in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in United Kingdom due to public health guidance (IV) (NCT03307746)
  • 31 May 2024 Efficacy and adverse events data from a phase II trial in Biliary cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASC0-2024)
  • 19 Jan 2024 Celldex Therapeutics and University of Virginia completes a phase I/II Mel-65 trial for Malignant melanoma in USA (IV) (NCT03617328)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top